[go: up one dir, main page]

NZ503559A - Compositions and methods for the control of smoking containing a xanthine oxidase inhibitor - Google Patents

Compositions and methods for the control of smoking containing a xanthine oxidase inhibitor

Info

Publication number
NZ503559A
NZ503559A NZ503559A NZ50355998A NZ503559A NZ 503559 A NZ503559 A NZ 503559A NZ 503559 A NZ503559 A NZ 503559A NZ 50355998 A NZ50355998 A NZ 50355998A NZ 503559 A NZ503559 A NZ 503559A
Authority
NZ
New Zealand
Prior art keywords
compositions
control
xanthine oxidase
smoking
oxidase inhibitor
Prior art date
Application number
NZ503559A
Inventor
Michael Glenn King
Original Assignee
Michael Glenn King
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michael Glenn King filed Critical Michael Glenn King
Publication of NZ503559A publication Critical patent/NZ503559A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Medical Informatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compositions for the control of smoking are disclosed, the compositions comprising: (a) A xanthine oxidase inhibitor; (b) A phosphate or a compound capable of releasing phosphate on administration to a subject; and optionally (c) A sugar; and still further optionally (d) One or more pharmaceutically acceptable carriers or excipients. There are also described methods for the control of smoking, which comprises administering to a subject in need of such treatment the aforementioned composition.
NZ503559A 1997-09-04 1998-09-03 Compositions and methods for the control of smoking containing a xanthine oxidase inhibitor NZ503559A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO8979A AUPO897997A0 (en) 1997-09-04 1997-09-04 Improved compositions and methods for the control of smoking
PCT/AU1998/000711 WO1999011257A1 (en) 1997-09-04 1998-09-03 Improved compositions and methods for the control of smoking

Publications (1)

Publication Number Publication Date
NZ503559A true NZ503559A (en) 2002-12-20

Family

ID=3803265

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ503559A NZ503559A (en) 1997-09-04 1998-09-03 Compositions and methods for the control of smoking containing a xanthine oxidase inhibitor

Country Status (6)

Country Link
EP (1) EP1011662A4 (en)
JP (2) JP3615704B2 (en)
AU (1) AUPO897997A0 (en)
CA (1) CA2302248A1 (en)
NZ (1) NZ503559A (en)
WO (1) WO1999011257A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115444161B (en) * 2022-09-28 2023-05-09 东莞市鸿馥生物科技有限公司 Electronic cigarette liquid containing traditional Chinese medicine extract and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983002892A1 (en) * 1982-02-22 1983-09-01 Talapin, Vitaly, Ivanovich Medicinal preparation having antinicotine effect and method for obtention thereof
JPS63203624A (en) * 1987-02-18 1988-08-23 Katsumi Mizumaki Drug for stopping smoking
JPS6440432A (en) * 1987-08-04 1989-02-10 Tadao Inagaki Solution making people come to dislike smoking
AU7438894A (en) * 1993-10-05 1995-04-27 Michael Glenn King Method for the treatment of diseases caused by compromised xanthine metabolism and methods for detecting said diseases
CN1089834A (en) * 1993-10-14 1994-07-27 王子芸 The prescription of chewing gum for giving-up smoking and processing technique
AUPM835394A0 (en) * 1994-09-23 1994-10-13 King, Michael G. Dr. Method for controlling or eliminating the need to smoke tobacco, and for treating ailments which may lead to the said need

Also Published As

Publication number Publication date
EP1011662A4 (en) 2002-08-21
JP2001514220A (en) 2001-09-11
JP3615704B2 (en) 2005-02-02
EP1011662A1 (en) 2000-06-28
AUPO897997A0 (en) 1997-09-25
WO1999011257A1 (en) 1999-03-11
JP2004231662A (en) 2004-08-19
CA2302248A1 (en) 1999-03-11

Similar Documents

Publication Publication Date Title
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
WO2000016762A3 (en) Method for reducing nicotine dependency
CA2170255A1 (en) Pharmaceutical Composition for Immunoenhancement Therapy
BG106360A (en) Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
WO2000007979A3 (en) Compounds and compositions for delivering active agents
NO971889L (en) Compounds and compositions for delivery of active agents
NZ514574A (en) Novel method of treatment
WO1998033491A3 (en) Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
PL340659A1 (en) Spheroides, method of obtaining them and pharmacological compositions
MX9702163A (en) Compositions and methods for the control of smoking.
PL330910A1 (en) Mode of administering inhibitors of h+, k+ - atpase
EP1008344A4 (en) The new use of dicaffeoylquinic acid for treating hepatitis b and the diseases related with retrovirus, and the new caffeoylquinic acid derivatives
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
IE881410L (en) Anticoccidial composition
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
GB9907571D0 (en) Compounds
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
AU5158000A (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
EP1073436A4 (en) IMPROVED METHOD FOR ERADICATION OF $i(HELICOBACTER PYLORI)
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
NZ503559A (en) Compositions and methods for the control of smoking containing a xanthine oxidase inhibitor
CA2361081A1 (en) Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis
WO2001019357A3 (en) Combination preparation for the treatment of sexual dysfunction
HK1045987A1 (en) 3-amino-2-benzyl-1-phenyl-propane derivatives

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired